Results 1 to 10 of about 4,875 (50)

Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus

Frontiers in Bioengineering and Biotechnology, 2023
Arming oncolytic viruses with transgenes encoding immunomodulators improves their therapeutic efficacy by enhancing and/or sustaining the innate and adaptive anti-tumoral immune responses.
Christelle Remy, Elodie Pintado, Marshall Dunlop, Shirley Schön, Patricia Kleinpeter, Homa Rozanes, Laetitia Fend, Renée Brandely, Michel Geist, Delphine Suhner, Eline Winter, Nathalie Silvestre, Claire Huguet, Peter Fitzgerald, Eric Quéméneur, Jean-Baptiste Marchand   +15 more
doaj   +1 more source

Intravenous injection of a novel viral immunotherapy encoding human interleukin-7 in nonhuman primates is safe and increases absolute lymphocyte count

Human Vaccines & Immunotherapeutics, 2022
Persistence of an immunosuppression, affecting both the innate and adaptive arms of the immune system, plays a role in sepsis patients’ morbidity and late mortality pointing to the need for broad and effective immune interventions.
Charles-Antoine Coupet, Clarisse Dubois, Alexeï Evlachev, Nadine Kehrer, Marie Baldazza, Sam Hofman, Michel Vierboom, Perrine Martin, Geneviève Inchauspe   +8 more
doaj   +1 more source

Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs

Scientific Reports, 2021
Oncolytic virotherapy is an emerging strategy that uses replication-competent viruses to kill tumor cells. We have reported the oncolytic effects of TG6002, a recombinant oncolytic vaccinia virus, in preclinical human xenograft models and canine tumor ...
Jérémy Béguin, Murielle Gantzer, Isabelle Farine, Johann Foloppe, Bernard Klonjkowski, Christelle Maurey, Éric Quéméneur, Philippe Erbs   +7 more
doaj   +1 more source

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject ‘cold’ tumors

Journal for ImmunoTherapy of Cancer, 2022
Background Immune checkpoint blockade (ICB) is a clinically proven concept to treat cancer. Still, a majority of patients with cancer including those with poorly immune infiltrated ‘cold’ tumors are resistant to currently available ICB therapies ...
Laetitia Fend, Eric Quemeneur, Monika Semmrich, Jean-Baptiste Marchand, Matilda Rehn, Nathalie Silvestre, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Björn Frendeus, Petra Holmkvist, Carolin Svensson, Christelle Remy, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L Cleary, Mimoza Bodén   +17 more
doaj   +1 more source

IL-7 producing immunotherapy improves ex vivo T cell functions of immunosenescent patients, especially post hip fracture

Human Vaccines & Immunotherapeutics, 2023
Following acute stress such as trauma or sepsis, most of critically ill elderly patients become immunosuppressed and susceptible to secondary infections and enhanced mortality.
Chrystel Marton, Alix Minaud, Charles-Antoine Coupet, Manon Chauvin, Jamila Dhiab, Hélène Vallet, Jacques Boddaert, Nadine Kehrer, Bérangère Bastien, Geneviève Inchauspe, Luc Barraud, Delphine Sauce   +11 more
doaj   +1 more source

Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs

BMC Veterinary Research, 2020
Background Cancer is a leading cause of mortality for both humans and dogs. As spontaneous canine cancers appear to be relevant models of human cancers, developing new therapeutic approaches could benefit both species.
Jérémy Béguin, Virginie Nourtier, Murielle Gantzer, Sandrine Cochin, Johann Foloppe, Jean-Marc Balloul, Eve Laloy, Dominique Tierny, Bernard Klonjkowski, Eric Quemeneur, Christelle Maurey, Philippe Erbs   +11 more
doaj   +1 more source

Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination

Clinical & Translational Immunology, 2022
Objective Antitumor viral vaccines, and more particularly poxviral vaccines, represent an active field for clinical development and translational research.
Rodrigo Nalio Ramos, Caroline Tosch, Fiorella Kotsias, Marie‐Christine Claudepierre, Doris Schmitt, Christelle Remy‐Ziller, Chantal Hoffmann, Marine Ricordel, Virginie Nourtier, Isabelle Farine, Laurence Laruelle, Julie Hortelano, Clementine Spring‐Giusti, Christine Sedlik, Christophe Le Tourneau, Caroline Hoffmann, Nathalie Silvestre, Philippe Erbs, Kaidre Bendjama, Christine Thioudellet, Eric Quemeneur, Eliane Piaggio, Karola Rittner   +22 more
doaj   +1 more source

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

Human Vaccines & Immunotherapeutics, 2020
Treatment of chronic hepatitis B (CHB) typically requires life-long administration of drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity and resolution of infection.
Fabien Zoulim, Claire Fournier, François Habersetzer, Martin Sprinzl, Stanislas Pol, Carla S Coffin, Vincent Leroy, Mang Ma, Heiner Wedemeyer, Ansgar W Lohse, Robert Thimme, Karine Lugardon, Perrine Martin, Bérangère Bastien, Benoit Sansas, Nathalie Adda, Celine Halluard, Kaïdre Bendjama, Maud Brandely, Geneviève Inchauspé   +19 more
doaj   +1 more source

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

Journal for ImmunoTherapy of Cancer, 2017
Background Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival in comparison to that of patients ...
Caroline Tosch, Bérangère Bastien, Luc Barraud, Benoit Grellier, Virginie Nourtier, Murielle Gantzer, Jean Marc Limacher, Eric Quemeneur, Kaïdre Bendjama, Xavier Préville   +9 more
doaj   +1 more source

Inactivation of the lysine binding sites of human plasminogen (hPg) reveals novel structural requirements for the tight hPg conformation, M-protein binding, and rapid activation

Frontiers in Molecular Biosciences, 2023
Accelerated activation of the human plasminogen zymogen (hPg) to two-chain active plasmin (hPm) is achieved following conformational changes induced by ligand-binding at the lysine-binding sites (LBSs) in four of the five hPg kringle domains.
Yetunde A. Ayinuola, Francis J. Castellino, Francis J. Castellino   +2 more
doaj   +1 more source